Chronic obstructive pulmonary disease (COPD, or slow-onset lung) is a chronic respiratory disease. Globally, as many as 600 million people suffer from COPD, which can cause 2.75 million deaths each year. The total number of COPD patients in China can reach 27 million each year. At present, COPD cannot be cured, but medication can improve patients’ symptoms, improve their quality of life and reduce the acute exacerbation of the disease. COPD treatment is divided into stable treatment and acute exacerbation treatment, and the treatment of stable COPD is mainly graded, i.e., the treatment plan is selected according to the severity of COPD, which is divided into pharmacological treatment and non-pharmacological treatment. Here, we will only talk about pharmacological treatment. At present, drug therapy is still the main means of treating COPD. There are several types of drugs used to treat COPD: bronchodilators, glucocorticoids and other drugs such as expectorants, immunomodulators, vaccines, etc. Bronchodilators can relax bronchial smooth muscle, dilate bronchi and relieve airflow restriction, and are the main treatment for controlling COPD symptoms. Compared with oral medications, inhalation dosage forms have fewer adverse effects, and therefore, inhalation therapy is mostly advocated. Bronchodilators are divided into short-acting and long-acting preparations according to the duration of action, mainly including the following three kinds: 1, β2 agonists: short-acting system such as salbutamol, terbutaline, etc., long-acting preparations such as procatheol, salmeterol, formoterol, etc.; 2, anticholinergics: short-acting preparations such as ipratropium bromide, long-acting preparations such as tiotropium bromide; 3, theophylline drugs: short-acting forms such as aminophylline, dihydroxypropyl theophylline etc., long-acting formulations such as extended-release theophylline, enanthate, etc. Clinically, one or more of the above drugs are often used for treatment according to the action of the drug and the patient’s treatment response. The combination of drugs with different mechanisms of action and duration of action can enhance the bronchodilator effect and reduce adverse effects. Short-acting agents are suitable for COPD patients in various classifications, and can be used in combination with one or more of these drugs as needed; long-acting agents are suitable for COPD patients with moderate or higher classifications, and can be used in combination with one or more of these drugs. Glucocorticosteroids are also commonly used in the treatment of COPD. Long-term regular inhalation of glucocorticosteroids can reduce the frequency of acute exacerbations and improve the quality of life, and are indicated for FEV1 as a percentage of the expected value.